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SllmmllL~ 
We sought to investigate the usefulness of the adeno-associated  virus 2 (AAV)-based vectors 
to suppress the excess production of the human cx-globin gene product towards developing a 
treatment modality for B-thalassemia  since accumulation of free c~-globin reduces the lifespan 
of red blood cells in these patients. We constructed recombinant AAV virions containing the 
human ~x-globin gene sequences in antisense orientation driven by the herpesvirus thymidine 
kinase (TK) promoter, the SV40 early gene promoter, and the human cx-globin gene promoter, 
respectively, as well as a bacterial gene for resistance to neomycin (neo  ~) as a selectable marker. 
These recombinant virions were used to infect a human erythroleukemia cell line (K562)  that 
expresses high levels of c~-globin mRNA. Clonal populations of neo  p" cells were obtained after 
selection with the drug G418, a neomycin analogue. Total genomic DNA samples isolated from 
these cells were analyzed on Southern blots to document stable integration of the transduced 
neo and o~-globin genes. Total cellular RNA samples isolated from mock-infected and recombinant 
virus-infected cultures were also analyzed by Northern blots. Whereas the TK promoter-driven 
antisense cx-globin sequences showed no inhibition of expression of the endogenous ol-globin 
gene, the SV40 promoter and the oe-globin gene promoter-driven antisense ot-globin sequences 
suppressed the expression of this constitutively over-expressed gene by approximately 29 and 
91%, respectively, at the transcriptional level. These studies suggest the feasibility of utilizing 
the AAV-based antisense gene transfer  approach in the potential treatment of t3-thalassemia. 
deno-associated virus 2 (AAV) is a nonpathogenic human 
parvovirus that requires coinfection with either adeno- 
virus, herpesvirus, or vaccinia virus for its optimal growth 
and replication (1). In the absence of a helper virus, the AAV 
genome integrates into chromosomal DNA in a site-specific 
manner on chromosome 19 in human cells (2-4). The AAV 
genome is a single-stranded DNA containing identical in- 
verted terminal repeats (ITRs) that act as the sole c/s-acting 
elements for the viral DNA replication (5-7). Several AAV- 
based recombinant virions have been constructed by replacing 
the entire viral genome with a foreign DNA between the 
two ITRs, and have been shown to be functionally active 
upon infection of a variety of established cell lines and pri- 
mary ceU cultures in vitro (8-10). 
The nonpathogenic nature  of AAV, coupled with  the 
remarkable site specificity of integration, has added to its de- 
sirable features  as a vector for gene therapy (8-13).  In the 
current study, we investigated the potential application of 
the AAV-based vector system as a treatment modality for 
/3-thalassemia, a heritable disorder characterized by defective 
synthesis of 3-globin chains. In the homozygous condition, 
13-thalassemia is also characterized by accumulation of exces- 
sive free cx-globin chains which results in premature death 
of erythroid progenitor cells before they reach the reticulo- 
cyte stage (14). This imbalanced production of globin chains 
results in red cell damage shortening their lifespan. A mech- 
anism that could control the excess  production of free ~x-globin 
chains would be expected to largely benefit in the ameliora- 
tion of clinical  severity of this disease. 
The strategy we employed was based on suppression of 
the augmented ot-globin levels at the transcriptional stage 
through the production of antisense ol-globin RNA sequences 
mediated by AAV. We observed significant inhibition of ex- 
pression of the endogenous oe-globin gene in K562 cells upon 
infection with recombinant AAV virions harboring the an- 
tisense human o~-globin DNA sequences driven either by the 
SV40 early promoter or the human o~-globin gene promoter. 
We suggest that the AAV-based  vector system may prove useful 
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in general,  and 13-thalassemia  in particular. 
Materials  and  Methods 
Plasmids,  Viruses,  and  Cells.  Recombinant  clones  of  AAV 
plasmids have been described (15, 16), and were obtained from Dr. 
K. J. Samulski (University of North Carolina, Chapel Hill, NC). 
Two recombinant AAV plasmids containing the neo R gene driven 
by either the SV40 promoter (pAAV-Neo), or the TK promoter 
(pWP-19), have also been described (17, 18). A recombinant plasmid 
containing the genomic copy of human c~-globin gene (pTRZ1) 
was kindly provided by Dr. George Stamatoyannopoulos (Univer- 
sity of Washington,  Seattle,  WA).  A recombinant plasmid con- 
taining the SV40 promoter-driven chloramphenicol acetyl trans- 
ferase (CAT) gene (pCAT-control)  was purchased from Promega 
Biotech (Madison, WI).  Human adeno-associated  virus 2 (AAV- 
2H), and human adenovirus 2 (Ad2) viral stocks were provided, 
respectively, by Dr. K. I. Betas, (Cornell University Medical Col- 
lege, New York) and Dr. K. H. Fife (Indiana  University School 
of Medicine,  Indianapolis,  IN), and were grown and maintained 
as previously described  (19-21).  The human erythroleukemia cell 
line, K562, was obtained from the American Type Culture Collec- 
tion (R.ockville, MD), and maintained in IMDM supplemented with 
10%  FBS. 
Construction  of Recombinant  Plasmids  and  Viruses.  The overall 
strategy for the construction of the three different recombinant 
AAV plasmids  is illustrated in Fig.  1. Plasmid pSP-2, containing 
the thymidine kinase (TK) promoter-driven human o~-globin gene 
sequence  in  antisense  orientation (Fig.  1 A) was  constructed as 
follows: the c~-globin fragment was isolated from plasmid pTRZ1 
using restriction enzymes NcoI and PvulI, and cloned between 
BgllI and SmaI sites of plasmid pTK-Neo after treatment with Pollk 
by the standard methods described in Sambrook et al. (22) to yield 
a plasmid, designated pSP-1, which also contained the TK polyad- 
enylation (poly A) signal sequence. A DNA fragment containing 
the TK promoter-driven antisense c~-globin gene was excised from 
plasmid pSP-1 using EcoRI and HindlII and cloned at the EcoRI 
site of plasmid pAAV-Neo after treatment with Pollk to yield a 
plasmid,  designated pSP-2.  This plasmid contains the antisense 
c~-globin sequences driven by the TK promoter, and the neo R gene 
driven by the SV40 promoter. Plasmid pSP-12, containing the SV- 
40 promoter-driven or  gene in antisense orientation, and the 
TK promoter-driven neo R  gene (Fig.  1 B),  was  constructed by 
replacing the CAT coding sequences in pCAT-control by the c~-glo- 
bin sequences in antisense orientation to generate a plasmid, desig- 
nated pSP-7, in which the SV40 poly A signal was retained at the 
3' end. Further, the SV40 promoter-driven antisense c~-globin se- 
quences were isolated from pSP-7 using EcoRI and XbaI, and cloned 
at  the BamHI  site of pWP-19  after treatment with  PolIk.  The 
resulting plasmid,  designated pSP-12, contains SV40  promoter- 
driven antisense c~-globin sequences and the TK promoter-driven 
neo ~" gene sequences  flanked  by the AAV-ITRs.  Plasmid  pSP-17 
was constructed with the human c~-globin gene promoter-driven 
antisense  c~-globin sequences,  and the TK promoter-driven neo ~ 
(Fig.  1 C).  Plasmid  pSP-o~, containing the entire coding region 
as well as the promoter region of the human c~-globin sequences, 
was digested with NcoI and HindIII to remove the coding region 
of the o~-globin coding sequence, and a 1.0-kh DNA fragment iso- 
lated from Hinfl-digestion of plasmid  pTRZ1 that contained the 
c~-globin coding region was cloned in antisense  orientation after 
treatment with PolIk to yield a plasmid,  designated pSP-15. The 
c~-globin poly A sequence  was retained in pSP-15. The c~-globin 
promoter-driven antisense c~-globin sequences were further cloned 
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Figure  1. 
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Construction of antisense human ot-globin gene-containing recombinant AAV plasmids and virions. The overall strategy for construction 
of the recombinant AAV genomes  containing antisense c~-globin  sequences  driven  by the TK promoter (vTKp-globin-~;  A), the SV40 promoter (vSV40p- 
globin-ot; B), and the c~-globin promoter (votp-globin-c~; C), is described under Materials and Methods. 
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to generate a recombinant  plasmid, designated  pSP-17. 
All three recombinant  AAV genomes were rescued from their 
respective phsmids,  packaged into mature AAV virions,  as pre- 
viously described (23), and designated vTKp-globin-o~, vSV40p- 
globin-~, and vo~p-globin-c~,  respectively. The viral titers were de- 
termined on quantitative DNA slot blots as p~viously described  (24). 
Recombinant Virus Infections and Selection of neo  ~ Colonies.  K562 
cells were infected with the recombinant  viruses at a multiplicity 
of infection  (m.o.i.) of I  in 0.5 ml of IMDM. Infection was al- 
lowed to proceed at 37~  for 2 h after which the cells were plated 
in 10 ml IMDM supplemented with 10% FBS and grown at 37~ 
48 h post-infection (p.i.), the drug G418 was added to the medium 
at a final active concentration  of 400/~g/ml,  and the cultures were 
maintained  for at least 2 wk before selecting the he0  ~ clonal cell 
populations.  The neo  ~ colonies were propagated  in IMDM sup- 
plemented  with  10% FBS and 400/~g/ml G418. 
Southern Blot Analysis for Viral Integration.  Total  genomic DNA 
samples isohted from mock-infected,  or the recombinant  virus- 
infected,  neo  ~ clones of K562  cells were subjected to digestion 
with a variety of  restriction endonudeases and analyzed on Southern 
blots  as  previously  described  (25). 32P-hbeled ot-globin-  and 
neomycin-specific  DNA probes were used to hybridize to the filters 
and autoradiographed. 
Northern Blot Analysis of Expression of the Endogenous ot-Globin 
Gen~  Total  cellular RNA was isohted from the recombinant virus- 
infected he0  ~ colonies of K562 cells as well as from mock-infected 
K562  ceUs following  standard  methods (26). Northern blots of 
equivalent amounts of different RNA samples were probed with 
3zp-hbeled  c~-globin-,  /~-actin-,  and  neomycin-specific DNA 
probes. The levels  of  expression of the endogenous c~-globin RNAs 
were quantitated  by scanning the autoradiograms  using a video 
densitometer (model620; Bio-Rad Laboratories, Richmond, CA). 
Figure 2.  Southern  blot analysis  of stable transduction of the recom- 
binant AAV genomes  in K562  cells. Total  genomic  DNA samples  isolated 
from K562  cells  after  mock-infection  (lanes I, 5, 9), or transduction with 
vTKp-globin-o~ (lanes 2, 6, 10), vSV40p-globin-,v (lanes 3,  7, 11), and 
vo~p-globin-ot  (lanes 4, 8, 12), were cleaved  with the indicated restriction 
endonucleases and analyzed on Southern blots using a neo-spedfic DNA 
probe as described  under Materials and Methods. HindIII-cleaved  PM2 
DNA fragments were codectrophoresed  as size-markers. 
Results 
Successful  Transduction  of K562  Cells with the Recombinant 
AAV  Vectors.  The  recombinant  AAV  genomes  we  con- 
structed in these studies were "~5.0 kb in length, and could 
thus be successfully packaged into mature virions to generate 
vTKp-globin-c~,  vSV40p-globin-ot, and voq~-globin-ot recom- 
binant AAV virions, respectively (Fig.  1). Since the recom- 
binant viral genomes also contained a neo  R selectable-marker 
gene, upon infection of K562 cells with these virions, G418- 
resistant  cell populations  could be readily obtained.  These 
donal cell populations for each recombinant virus were pooled 
and their genomic DNA was analyzed on Southern blots as 
described under  Materials  and  Methods.  A  representative 
Southern blot probed with a neo-speciiic DNA probe is shown 
in  Fig.  2. 
As is evident, none of  the DNA samples isolated from mock- 
infected K562 cells contained specific neo-hybridizing bands. 
However, in DNA samples isolated from each of the recom- 
binant virus-infected cell populations, the probe detected sev- 
eral distinct hybridizing fragments suggesting stable integra- 
tion of the recombinant viral genomes into the chromosomal 
DNA. Similar results were obtained when an o~-globin-specific 
DNA was used as a probe except for detection of the endog- 
enous alleles  (data not  shown). 
Expression Analysis of the Endogenous cr-globin Gen~  It was 
next of interest to determine whether the transduced antisense 
c~-globin sequences modulated the levels of expression of the 
constitutively expressed c~-globin  gene in K562 cells.  Total 
KNA samples isolated from mock-infected,  or the recom' 
binant virus-infected cells were analyzed on Northern blots 
as described under  Materials  and Methods.  Such a blot is 
depicted in Fig.  3. 
It is evident that  when a neo-spedfic  DNA was used as 
probe (Fig. 3 A), no hybridization was detected in mock-in- 
fected K562 cells (Fig. 3, lane 1), whereas the probe detected 
specific RNA transcripts in the three recombinant virus-in- 
fected cultures (Fig. 3, lanes 2-4). The sizes of the transcripts 
correspond to their respective genomes. When the same blot 
was probed with an ot-globin probe (Fig. 3 B), mock-infected 
(Fig. 3, lane I) as well as vTKp-globin-o~ virus-infected (Fig. 
3, lane 2) K562 showed abundant expression of the endoge- 
nous ol-globin gene.  However, cell populations  transduced 
with vSV4Op-globin-c~ (Fig. 3, lane 3) and voq>-globin-c~  (Fig. 
3, lane 4) virions showed a dear suppression of expression 
of the endogenous gene. Densitometric analyses  of the hy- 
bridization signals revealed the extent of this suppression to 
be "~29%  with  vSV4Op-globin-ot,  and  •91%  with  vo~p- 
globin-o~ recombinant virions with reference to the levels of 
/3-actin  mRNA (Fig.  3 C).  These levels also corresponded 
well with ethidium bromide-induced fluorescence intensities 
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c~-globin gene in K562 cells. Total RNA samples isohted from mocb 
infected  (lane  l), r  virus-infected  (lane  2), vSV40p-globin-c, 
virus-infected  (lane  3), and voq~-globin-c~  virus-infected  (lane  4) K562 cells 
were analyzed  on Northern blots using the following  DNA probes:  neo 
(A), a-globin (B), and B-actin (C) as described  under Materials and 
Methods.  Ethidium  bromide-induced  fluorescence  of  28s and 18s ribosomal 
RNAs is also shown (D). 
of 28s and 18s ribosomal RNA bands in these cell popula- 
tions (Fig.  3 D). We also noted that expression of the neo- 
specific KNA transcripts was significantly lower with the 
TK promoter than with the SV40 promoter (Fig. 3 A) indi- 
cating the relative inefficiency of the TK promoter function 
compared with  that of the SV40 promoter in K562 cells. 
These data suggest that it may indeed be feasible to em- 
ploy the AAV-based antisense vectors to modulate the ex- 
pression of the constitutively over-expressed c~-globin gene 
in human hematopoietic cells. 
Di~umon 
The potential application of the AAV-based vector system 
for the purpose of gene therapy in humans is gaining atten- 
tion (8-13).  That the AAV-based vectors may prove to be 
a useful alternative to the more commonly used retrovirus- 
based vectors, stems from the fact that AAV is a nonpatho- 
genic virus whereas retroviruses are intimately associated with 
neoplastic events (27).  AAV has thus far not been shown to 
be associated with any malignant disease (28), and interest- 
ingly, AAV has been shown to possess anti-oncogenic prop- 
erties both in vitro and in vivo (29-32). 
Of the several human diseases amenable to genetic correc- 
tion, those affecting the hematopoietic system appear to be 
potential candidates for gene therapy. In the case of B-tha- 
lassemia,  which is characterized by the defective B-glohin 
production, a mechanism to deliver a functional B-globin gene 
would be a preferred form of treatment. Indeed, in our re- 
cent studies with the recombinant AAV vector system, we 
have documented successful transduction and erythroid cell- 
specific expression of  a normal human B-globin gene in human 
hematopoietic cells in vitro (32a).  It is also noteworthy that 
Walsh et al. (8) have recently described the construction of, 
and in vitro expression from, a recombinant AAV-q,-globin 
vector. 
A  second line of therapeutic measure that could amelio- 
rate the severity of this disease would be to suppress  the ac- 
cumulation of excessive levels of the c~-globin chains in red 
blood cells which leads to their premature destruction. The 
antisense strategy that we employed in our present studies 
might prove as a useful mode of treatment for such a defect. 
The extent of suppression was highest with the c~-globin gene 
promoter-driven antisense sequences. This probably suggests 
the maximal efficiency of a natural promoter in transcrip- 
tional activation by tmns-acting factors compared with the 
heterologous promoters. The mechanism of antisense RNA 
inhibiting the expression of a target gene is not clearly un- 
derstood. Yet, in principle, the antisense RNA could act at 
the following levd(s): transcription, mRNA processing, trans- 
port out of the nucleus, translation, and/or general stability 
of the mRNA (33). A cogent example of near-total suppres- 
sion in vitro of HIV-1 replication mediated by an antisense 
AAV vector has recently been provided by Chatterjee et al. 
(9).  In our studies, no attempts were made to control the 
levels of antisense RNA production, but we presume that 
most of the antisense RNA transcripts that were generated 
were utilized in hybridization with the complementary target 
c~-globin  mKNA.  Using strand-specific RNA probes,  we 
could not detect any significantly free antisense transcripts 
in K562 ceils transduced with the recombinant AAV virions, 
yet abundant expression of these transcripts was evident in 
transduced HeLa cells as determined by Northern blot anal- 
ysis  (data not shown). 
Although we were able to achieve high-level suppression 
of expression of the endogenous c~-globin gene in clonal popu- 
lations of relatively homogeneous K562 cells, it may be un- 
desirable to completely block the expression of the required 
basal amounts of the endogenous c~-globin gene in primary 
human hematopoietic cells by over-producing the antisense 
cr  RNA transcripts.  However, given the heterogeneous 
nature of the primary human hematopoietic cells, we believe 
this unlikdy to be the case. Whether this strategy with pri- 
mary cultures will prove to be effective in vitro remains to 
be determined. It also remains to be ascertained whether this 
treatment modality will be safe and efficacious in an animal 
model in vivo, before its potential use in human gene therapy. 
This form of gene transfer using antisense RNA production 
may also prove to be useful in a wide variety of disease condi- 
tions that are characterized by undesirable over-expression of 
endogenous genes as well as that from infectious agents. 
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